Core Viewpoint - The Hong Kong stock market has seen a continuous share buyback trend since 2026, with leading companies like Yidu Tech (02158) actively participating to demonstrate confidence in their intrinsic value and future development [1] Group 1: Share Buyback Activity - Yidu Tech announced a share buyback on February 16, repurchasing 404,000 shares at approximately HKD 5.91 per share, totaling nearly HKD 2.4 million [1] - This marks the 15th buyback since the beginning of 2026, with a cumulative expenditure of nearly HKD 67 million [1] - The buyback activity has been characterized by high frequency and steady intensity, with 15 buybacks completed in less than a month since the first buyback on January 26 [1] Group 2: Business Developments - Yidu Tech's recent collaboration with Huazhong University of Science and Technology's Tongji Hospital on a multimodal AI database project for gastrointestinal tumors has been selected for the Ministry of Industry and Information Technology's 2025 AI medical device innovation initiative [1] - The company's growth prospects have been recognized by institutions, with Citigroup maintaining a "Buy" rating and raising the target price to HKD 11 in February [1]

Group 1 - The core viewpoint of the article highlights the ongoing share buyback trend in the Hong Kong stock market since 2026, with leading companies like Yidu Tech (02158) actively participating to demonstrate confidence in their intrinsic value and future development [1] Group 2 - On February 16, Yidu Tech announced a share buyback of 404,000 shares at approximately HKD 5.91 per share, costing nearly HKD 2.4 million, marking its 15th buyback since 2026 and totaling close to HKD 67 million in expenditures [1] - The buyback activity of Yidu Tech is characterized by "high frequency and steady strength," having completed 15 buybacks in less than a month since the first buyback on January 26 [1] - Yidu Tech's business prospects have been positively impacted by recent developments, including the successful selection of a multimodal AI database project for gastrointestinal tumor diagnosis in collaboration with Huazhong University of Science and Technology [1] - Citigroup maintained a "buy" rating for Yidu Tech in February and raised its target price to HKD 11, reflecting institutional recognition of the company's growth potential [1]

Company Summary - Yidu Tech (02158) announced a share buyback on February 11, repurchasing over 480,000 shares at approximately HKD 6 per share, totaling nearly HKD 3 million, marking the thirteenth consecutive trading day of intensive buybacks, with a cumulative buyback amount exceeding HKD 61 million, demonstrating long-term confidence in the company's value [1][1][1] - Recently, Yidu Tech achieved a business milestone by successfully entering the national Ministry of Industry and Information Technology's "2025 Artificial Intelligence Medical Device Innovation Task" list with a multimodal AI database project for gastrointestinal tumor diagnosis in collaboration with Tongji Hospital of Huazhong University of Science and Technology [1][1][1] Industry Summary - The AI medical sector is at a critical juncture for commercialization, with CITIC Securities reporting that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market [1][1][1] - CITIC Securities predicts a fundamental change in the logic of AI medical applications by 2026, driven by clearer and stronger payment capabilities from payers this year, suggesting that 2026 will likely see greater certainty in AI medical commercialization and open up new commercial opportunities [1][1][1] - Key areas to focus on include AI pharmaceuticals, grassroots AI medical applications, medical data circulation and trading, AI pathological diagnosis, AI medical models, and C-end expansion channels, along with related targets [1][1][1]

Company Summary - Medicure Technology (02158) announced a share buyback on February 11, repurchasing over 480,000 shares at approximately HKD 6 per share, totaling nearly HKD 3 million, marking the thirteenth consecutive trading day of intensive buybacks, with a cumulative buyback amount exceeding HKD 61 million, demonstrating long-term confidence in the company's value [1][1][1] - Recently, Medicure Technology achieved a business milestone by successfully entering the national Ministry of Industry and Information Technology's 2025 AI medical device innovation project list with a multimodal AI database project for gastrointestinal tumor diagnosis and treatment in collaboration with Tongji Hospital of Huazhong University of Science and Technology [1][1][1] Industry Summary - The AI medical sector is at a critical juncture for commercialization, with CITIC Securities reporting that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market [1][1][1] - CITIC Securities predicts a fundamental change in the logic of AI medical applications by 2026, driven by clearer and stronger payment capabilities from payers this year, suggesting a stronger certainty for AI medical commercialization in 2026 [1][1][1] - Key areas for investment focus include AI drug development, grassroots AI medical applications, medical data circulation and trading, AI pathology diagnosis, AI medical models, and C-end expansion channels [1][1][1]